Mammalian target of rapamycin inhibition after solid organ transplantation: Can it, and does it, reduce cancer risk?

Mamatha Bhat, Kymberly D. Watt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor-based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.

Original languageEnglish (US)
Pages (from-to)654-663
Number of pages10
JournalClinical Transplantation
Volume29
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Organ Transplantation
Sirolimus
Chemoprevention
Neoplasms
Immunosuppressive Agents
Transplants
Cholangiocarcinoma
Biochemistry
Immunosuppression
Hepatocellular Carcinoma

Keywords

  • Everolimus
  • Immunosuppression
  • Malignancy
  • Mammalian target of rapamycin inhibitor
  • Sirolimus
  • Transplant

ASJC Scopus subject areas

  • Transplantation

Cite this

Mammalian target of rapamycin inhibition after solid organ transplantation : Can it, and does it, reduce cancer risk? / Bhat, Mamatha; Watt, Kymberly D.

In: Clinical Transplantation, Vol. 29, No. 7, 01.07.2015, p. 654-663.

Research output: Contribution to journalArticle

@article{be003ea656284517bf1e71c3f1b01524,
title = "Mammalian target of rapamycin inhibition after solid organ transplantation: Can it, and does it, reduce cancer risk?",
abstract = "The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor-based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.",
keywords = "Everolimus, Immunosuppression, Malignancy, Mammalian target of rapamycin inhibitor, Sirolimus, Transplant",
author = "Mamatha Bhat and Watt, {Kymberly D.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/ctr.12559",
language = "English (US)",
volume = "29",
pages = "654--663",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Mammalian target of rapamycin inhibition after solid organ transplantation

T2 - Can it, and does it, reduce cancer risk?

AU - Bhat, Mamatha

AU - Watt, Kymberly D.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor-based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.

AB - The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor-based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.

KW - Everolimus

KW - Immunosuppression

KW - Malignancy

KW - Mammalian target of rapamycin inhibitor

KW - Sirolimus

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84937162112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937162112&partnerID=8YFLogxK

U2 - 10.1111/ctr.12559

DO - 10.1111/ctr.12559

M3 - Article

C2 - 26094583

AN - SCOPUS:84937162112

VL - 29

SP - 654

EP - 663

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 7

ER -